

AMED DataBook

Second Term FY2020–FY2024

Japan Agency for Medical Research and Development

Preface

Japan Agency for Medical Research and Development (AMED) implemented the second five-year medium- to long-term plan period from FY2020 to FY2024. During this "Second Term", we promoted R&D in line with the six "Integrated Projects"* focusing on medical modalities, based on the government's second "Healthcare Policy". This also involved R&D related to specific disease areas that spanned across the "Integrated Projects".

We hope this "AMED DataBook – Second Term" will help you understand AMED's R&D implementation status.

December 2025

Japan Agency for Medical Research and Development

* The government's second "Healthcare Policy" states the six "Integrated Projects": Project for Advanced Drug Discovery and Development, Project for Medical Device and Healthcare, Project for Regenerative Medicine and Cell and Gene Therapies, Project for Genome and Health-Related Data, Project for Basic Medical Research, and Project for Seeds Development and Research Base.

Contents

Contents

Basic Information on Calculation in DataBook – Second Term

AMED accumulates and manages the information of contracted / granted R&D projects throughout their implementation period. Sections 1 through 4 have been compiled based on this AMED data (as of November 2025). (Data from Cyclic Innovation for Clinical Empowerment (CiCLE)*1 are excluded in Sections 1 through 4).

The statistics in 5.1 have been produced based on published data on AMED open calls (as of November 2025), and the statistics in 5.2 and 5.3 have been produced based on the Cross-ministerial R&D Management System (e-Rad) data.

The statistical unit is an awarded project. The number of projects and R&D funding are aggregated on an annual basis, and the projects implemented over a period of multiple years are counted in calculation for each implanting year. In these statistics, projects started their first year on or after April 1 of the fiscal year are treated as new projects, and others as ongoing projects.

R&D funding is the final contract / grant amount (including indirect costs) of a R&D project at the end of each fiscal year of the commissioned programs, grant programs or Special Fund Programs. When a project consists of subsidiary institutions or other subcontracted institutions under the supervision of a principal investigator (PI), R&D funding is the total amount of R&D funding for all the participating institutions for each fiscal year.

In these statistics, where necessary, numerical values are rounded. Therefore the sum of numerical values in breakdown do not always equal the grand total. The distribution ratio also does not total 100 in some cases.

These statistics have been produced based on the R&D tags showing the nature of R&D projects, which include "Target Disease", "Nature of Research", "R&D Phase", "Product Approval Category", "Disease Area" and "R&D Objective".

For "Target Disease", "Nature of Research", "R&D Phase", "Product Approval Category" and "Disease Area", one project is attached with one of these categorial tags.*2 For "R&D Phase", "Basic Study" and "Applied Study" are collectively treated as "Basic / Applied Studies" in these statistics. For "R&D Objective", multiple choices of the categorial tags are possible for a single project.

The classification of R&D tags has changed from FY2023. This DataBook aggregates R&D tags from FY2023 by replacing the R&D tags used until FY2022, in accordance with the data replacement rules established by AMED.

*1 Refer to 6.2 Glossary regarding Cyclic Innovation for Clinical Empowerment (CiCLE). ▶P36

*2 For "Disease Area", multiple choices of the categorial tags are possible for a single project in FY2020, and from FY2021 the tags for main "Disease Area" and other "Disease Areas" are attached to a single project. These statistics were produced using the main "Disease Area" data from FY2021 onwards.

Overview – Comparison between First and Second Term

No. of Projects and R&D Funding



Fig. 1 No. of projects



Fig. 2 R&D funding

- The number of projects is the sum of projects for each fiscal year. Projects implemented over a period of multiple years are aggregated each year of implementation.
- A total of 1,740 ongoing projects carried over from the First Term into the Second Term, with this number included in the totals in both terms.
- Source: AMED data (as of November 2025).

Overview – Comparison between First and Second Term

COVID-19



Fig. 3 No. of COVID-19-related budget projects



Fig. 4 R&D funding of COVID-19-related budget projects

- The number of projects is the sum of projects for each fiscal year. Projects implemented over a period of multiple years are aggregated each year of implementation.
- A total of 3 ongoing projects carried over from the First Term into the Second Term, with this number included in the totals in both terms.
- Source: AMED data (as of November 2025).

Overview – Comparison between First and Second Term

Research Institution



Fig. 5 No. of projects
by category of Research Institution



Fig. 6 R&D funding
by category of Research Institution

- Refer to 6.1 regarding the category of Research Institution. ▶P35
- Source: AMED data (as of November 2025). • The number of projects is the sum of projects for each fiscal year. Projects implemented over a period of multiple years are aggregated each year of implementation.
- Some figures are omitted in graphs.

Overview – Comparison between First and Second Term

Principal Investigators (PIs) of New Awards



Fig. 7 No. of PIs of new awards



Fig. 8 Average age of PIs of new awards

- Projects in the first term that were applied for and awarded by relevant ministries and agencies before the launch of AMED and then transferred to AMED in 2015 have been omitted.
- The new awards for a certain fiscal year are the projects launched in that fiscal year. • The number of PIs is the cumulative number for the new awards in each fiscal year.
- Source: The Cross-ministerial R&D Management System (e-Rad) (all as of November 2025). Note that data of researchers whose gender and birth date are unknown are not included.

Overview – Comparison between First and Second Term

Applications and Success Rates



Fig. 9 No. of applications and success rates

- Success rates are the percentage of all awards to the number of applications.
- Source: Published data on AMED open calls (as of November 2025).

1.1 No. of Projects and R&D Funding in Second Term



Fig. 1.1.1 No. of projects and R&D funding



Fig. 1.1.2 Trends in no. of projects and R&D funding

Table 1.1.1 Trends in no. of projects, R&D funding, and R&D funding per project

*COVID-19-related budget projects

	FY2020			FY2021			FY2022			FY2023			FY2024			Second Term Total		
	Total	Subset of total		Total	Subset of total		Total	Subset of total		Total	Subset of total		Total	Subset of total		Total	Subset of total	
		New	COVID-19*		New	COVID-19*		New	COVID-19*		New	COVID-19*		New	COVID-19*		New	COVID-19*
No. of projects	2,814	1,074	307	2,617	924	127	2,615	988	79	2,677	953	57	2,692	903	37	13,415	4,842	607
R&D funding (Billion JPY)	177.9	70.4	57.1	177.7	54.5	45.6	160.9	51.5	14.3	167.6	40.1	8.2	180.2	37.5	5.3	864.3	254.1	130.5
R&D funding per project (Billion JPY)	0.06	0.07	0.19	0.07	0.06	0.36	0.06	0.05	0.18	0.06	0.04	0.14	0.07	0.04	0.14	0.06	0.05	0.22

- The R&D funding per project is the average figure.
- Source: AMED data (as of November 2025).

1.2 Allocation of R&D Funding per Project: No. of Projects and R&D Funding



Fig. 1.2.1 Allocation of R&D funding per project based on no. of projects



Fig. 1.2.2 Allocation of R&D funding per project based on R&D funding

Table 1.2.1 No. of projects by fiscal year and by level of R&D funding per project

(Unit: Project)

	< 10M JPY		10M - 25M JPY		25M - 50M JPY		50M - 100M JPY		100M -500M JPY		500M - 1B JPY		1B JPY ≦	
	Total	New	Total	New	Total	New	Total	New	Total	New	Total	New	Total	New
FY2020	482	163	991	413	572	230	447	127	276	123	25	8	21	10
FY2021	445	167	990	375	487	165	419	122	236	77	22	13	18	5
FY2022	383	204	981	346	535	224	439	129	230	68	36	12	11	5
FY2023	382	174	993	385	582	216	458	122	211	49	28	2	23	5
FY2024	355	153	979	365	559	169	469	130	282	82	27	4	21	–
Total	2,047	861	4,934	1,884	2,735	1,004	2,232	630	1,235	399	138	39	94	25

Table 1.2.2 R&D funding by fiscal year and by level of R&D funding per project

(Billion JPY)

	< 10M JPY		10M - 25M JPY		25M - 50M JPY		50M - 100M JPY		100M -500M JPY		500M - 1B JPY		1B JPY ≦	
	Total	New	Total	New	Total	New	Total	New	Total	New	Total	New	Total	New
FY2020	2.9	0.9	16.1	6.7	20.4	8.4	31.4	9.0	53.8	24.8	17.6	5.6	35.8	14.9
FY2021	2.8	1.0	16.3	5.9	17.3	5.8	30.0	8.7	43.9	14.5	15.7	9.8	51.6	8.9
FY2022	2.3	1.2	15.7	5.5	18.4	7.5	31.7	9.3	44.3	12.5	23.8	7.7	24.7	7.8
FY2023	2.4	1.0	16.2	6.3	19.9	7.2	32.6	8.6	40.3	7.7	19.2	1.4	37.1	8.0
FY2024	2.2	0.9	15.9	5.9	18.6	5.3	33.9	9.6	52.9	12.9	18.6	2.9	38.1	–
Total	12.7	4.9	80.2	30.3	94.6	34.3	159.6	45.1	235.2	72.4	94.8	27.4	187.3	39.6

• Source: AMED data (as of November 2025).

1.3 By Integrated Project: No. of Projects and R&D Funding | 1) Second Term Total



Fig. 1.3.1 No. of projects by Integrated Project



Fig. 1.3.2 R&D funding by Integrated Project

Table 1.3.1 No. of projects and R&D funding by Integrated Project

Integrated Project	Abbreviation	No. of projects	R&D funding (Billion JPY)	R&D funding per project (Billion JPY)
Project for Advanced Drug Discovery and Development	Drugs	4,183	282.3	0.07
Project for Medical Device and Healthcare	Med. Devices	1,193	70.3	0.06
Project for Regenerative Medicine and Cell and Gene Therapies	Regenerative	1,171	97.5	0.08
Project for Genome and Health-Related Data	Genome	2,043	130.7	0.06
Project for Basic Medical Research	Basic Med.	2,338	98.8	0.04
Project for Seeds Development and Research Base	Seeds Dev.	2,255	108.7	0.05
Others (Special Fund Programs, etc.)	Others	232	76.0	0.33
Total		13,415	864.3	0.06

- The R&D funding per project is the average figure.
- Source: AMED data (as of November 2025).

1.3 By Integrated Project: No. of Projects and R&D Funding | 2) 5-years Trends



Fig. 1.3.3 Trends in no. of projects by Integrated Project



Fig. 1.3.4 Trends in R&D funding by Integrated Project

Table 1.3.2 Trends in no. of projects and R&D funding by Integrated Project

Integrated Project	Abbreviation	No. of projects					R&D funding (Billion JPY)				
		FY2020	FY2021	FY2022	FY2023	FY2024	FY2020	FY2021	FY2022	FY2023	FY2024
Project for Advanced Drug Discovery and Development	Drugs	911	885	823	786	778	67.6	79.3	55.1	43.0	37.3
Project for Medical Device and Healthcare	Med. Devices	285	201	217	259	231	24.5	10.4	10.5	11.6	13.3
Project for Regenerative Medicine and Cell and Gene Therapies	Regenerative	242	235	215	243	236	18.1	19.3	19.6	19.2	21.3
Project for Genome and Health-Related Data	Genome	421	381	405	404	432	26.7	25.5	22.6	26.6	29.2
Project for Basic Medical Research	Basic Med.	483	451	469	464	471	19.1	20.5	23.0	18.9	17.3
Project for Seeds Development and Research Base	Seeds Dev.	461	452	447	455	440	21.7	20.6	21.1	21.8	23.5
Others (Special Fund Programs, etc.)	Others	11	12	39	66	104	0.2	2.1	8.9	26.4	38.3
Total		2,814	2,617	2,615	2,677	2,692	177.9	177.7	160.9	167.6	180.2

• Source: AMED data (as of November 2025).

1.4 By Category of Research Institution: No. of Projects and R&D Funding | 1) Second Term Total



Fig. 1.4.1 No. of projects by category of Research Institution



Fig. 1.4.2 R&D funding by category of Research Institution

Table 1.4.1 No. of projects and R&D funding by category of Research Institution

Category of Research Institution	No. of projects	R&D funding (Billion JPY)
Universities, etc.	9,516	522.3
Incorporated Admin. Agencies / Nat'l Research Institutes	2,570	152.0
Companies, etc.	713	142.3
Local Public Entities, etc.	251	12.0
Incorporated Foundations / Associations, etc.	344	35.5
Others	21	0.2
Total	13,415	864.3

- Refer to 6.1 regarding the category of Research Institution. ▶P35
- Source: AMED data (as of November 2025).
- Some figures are omitted in graphs.

1.4 By Category of Research Institution: No. of Projects and R&D Funding | 2) 5-years Trends



Fig. 1.4.3 Trends in no. of projects by category of Research Institution



Fig. 1.4.4 Trends in R&D funding by category of Research Institution

Table 1.4.2 Trends in no. of projects and R&D funding by category of Research Institution

Category of Research Institution	No. of projects					R&D funding (Billion JPY)				
	FY2020	FY2021	FY2022	FY2023	FY2024	FY2020	FY2021	FY2022	FY2023	FY2024
Universities, etc.	1,993	1,867	1,850	1,908	1,898	112.2	96.8	95.1	106.6	111.6
Incorporated Admin. Agencies / Nat'l Research Institutes	541	503	514	506	506	29.7	27.0	33.8	31.2	30.3
Companies, etc.	160	122	126	138	167	29.4	44.0	21.3	18.9	28.7
Local Public Entities, etc.	51	54	55	49	42	1.9	2.2	3.0	2.7	2.2
Incorporated Foundations / Associations, etc.	63	65	66	73	77	4.7	7.7	7.6	8.2	7.4
Others	6	6	4	3	2	0.03	0.03	0.03	0.02	0.1
Total	2,814	2,617	2,615	2,677	2,692	177.9	177.7	160.9	167.6	180.2

• Refer to 6.1 regarding the category of Research Institution. ▶P35
• Source: AMED data (as of November 2025).
• Some figures are omitted in graphs.

1.5 By Target Disease | 1) No. of Projects

Table 1.5.1 No. of projects by Target Disease

Target Disease	No. of projects					
	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total
Certain infectious and parasitic diseases	273	288	311	345	338	1,555
COVID-19	246	109	88	11	8	462
Cancer (neoplasms)	592	632	589	601	650	3,064
Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism	35	26	34	123	117	335
Endocrine, nutritional and metabolic diseases	96	109	103	99	97	504
Mental and behavioural disorders	164	126	152	140	150	732
Diseases of the nervous system	192	190	203	316	324	1,225
Diseases of the circulatory system	130	149	145	168	155	747
Diseases of the respiratory system	60	59	51	62	62	294
Diseases of the digestive system	78	77	82	121	118	476
Diseases of the eye and adnexa	34	31	33	40	35	173
Diseases of the ear and mastoid process	15	14	15	16	18	78
Diseases of the skin and subcutaneous tissue	28	27	30	40	50	175
Diseases of the musculoskeletal system and connective tissue	71	67	82	70	70	360
Diseases of the genitourinary system	45	43	42	40	44	214
Pregnancy, childbirth and the puerperium	7	10	14	14	11	56
Certain conditions originating in the perinatal period	11	12	11	15	13	62
Congenital malformations, deformations and chromosomal abnormalities	39	46	46	15	17	163
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	50	32	35	4	6	127
Injury, poisoning and certain other consequences of external causes	59	42	41	6	7	155
External causes of morbidity and mortality	2	—	1	4	4	11
Factors influencing health status and contact with health services	10	10	4	8	9	41
Others	29	45	70	65	55	264
Diseases unspecified	518	468	432	354	333	2,105
Unknown	30	5	1	—	1	37
Total	2,814	2,617	2,615	2,677	2,692	13,415

- "Target Disease" have been aggregated by adding "Others" and "Diseases unspecified" to the large classification (chapter) of WHO's International Statistical Classification of Diseases and Related Health Problems (ICD-10, 2013).
- AMED confers one of the ICD-10 classification of diseases as a main "Target Disease" for each project. "Others" means projects targeting diseases that are not possible to classify in ICD-10.
- The category of "Diseases unspecified" includes research projects supporting the cross-disease research infrastructure, as well as basic research projects that have not yet specified "Target Disease" but may target a wide variety of diseases in the future. ICD-10 uses "Codes for special purposes" for a provisional assignment of new diseases of uncertain etiology or emergency use, and COVID-19 has been given a code for special purposes. In this table, it is displayed as COVID-19.
- Among the AMED R&D projects, the projects to which codes for special purposes apply consisted almost entirely of COVID-19 except two projects in FY2021 and one project in FY2022.
- Source: AMED data (as of November 2025).
- The data bars in this table assume, for each fiscal year, the value of 100 for the "Target Disease" of the largest number of projects in the year, and illustrate the size of the respective "Target Disease" by relative ratio. However, the "Unknown" category is excluded.

1.5 By Target Disease | 2) R&D Funding

Table 1.5.2 R&D funding by Target Disease

Target Disease	R&D funding (Billion JPY)					
	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total
Certain infectious and parasitic diseases	9.6	23.1	13.8	32.0	35.8	114.3
COVID-19	39.8	30.3	16.5	3.8	2.2	92.6
Cancer (neoplasms)	23.4	32.2	31.3	30.5	34.2	151.7
Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism	1.3	1.0	1.2	4.9	6.0	14.3
Endocrine, nutritional and metabolic diseases	3.2	5.4	4.5	5.6	5.1	23.8
Mental and behavioural disorders	7.8	6.5	9.0	6.2	7.0	36.5
Diseases of the nervous system	9.1	10.6	14.8	20.9	21.8	77.2
Diseases of the circulatory system	5.8	6.9	6.5	6.2	7.0	32.5
Diseases of the respiratory system	3.8	3.2	2.4	5.0	3.9	18.3
Diseases of the digestive system	3.1	3.0	3.0	5.5	5.9	20.5
Diseases of the eye and adnexa	1.7	1.6	1.5	2.9	3.7	11.4
Diseases of the ear and mastoid process	0.4	0.3	0.4	0.5	0.6	2.2
Diseases of the skin and subcutaneous tissue	1.0	1.3	1.7	1.8	1.9	7.6
Diseases of the musculoskeletal system and connective tissue	2.6	2.7	3.4	3.5	3.8	16.1
Diseases of the genitourinary system	1.8	1.3	1.4	1.5	1.8	7.8
Pregnancy, childbirth and the puerperium	0.2	0.2	0.6	0.3	0.3	1.7
Certain conditions originating in the perinatal period	0.4	0.5	0.5	0.5	0.5	2.4
Congenital malformations, deformations and chromosomal abnormalities	1.8	2.1	2.1	0.5	0.8	7.2
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	3.0	1.2	1.8	0.2	0.2	6.3
Injury, poisoning and certain other consequences of external causes	2.5	2.6	2.1	0.1	0.1	7.5
External causes of morbidity and mortality	0.02	—	0.01	0.2	0.1	0.3
Factors influencing health status and contact with health services	0.5	0.3	0.2	0.2	0.3	1.5
Others	1.3	1.5	4.7	4.9	5.1	17.4
Diseases unspecified	53.1	39.8	37.7	30.0	31.9	192.3
Unknown	0.8	0.1	0.01	—	0.03	0.9
Total	177.9	177.7	160.9	167.6	180.2	864.3

- "Target Disease" have been aggregated by adding "Others" and "Diseases unspecified" to the large classification (chapter) of WHO's International Statistical Classification of Diseases and Related Health Problems (ICD-10, 2013).
- AMED confers one of the ICD-10 classification of diseases as a main "Target Disease" for each project. "Others" means projects targeting diseases that are not possible to classify in ICD-10.
- The category of "Diseases unspecified" includes research projects supporting the cross-disease research infrastructure, as well as basic research projects that have not yet specified "Target Disease" but may target a wide variety of diseases in the future. ICD-10 uses "Codes for special purposes" for a provisional assignment of new diseases of uncertain etiology or emergency use, and COVID-19 has been given a code for special purposes. In this table, it is displayed as COVID-19.
- Among the AMED R&D projects, the projects to which codes for special purposes apply consisted almost entirely of COVID-19 except two projects in FY2021 and one project in FY2022.
- Source: AMED data (as of November 2025).
- The data bars in this table assume, for each fiscal year, the value of 100 for the "Target Disease" of the largest number of projects in the year, and illustrate the size of the respective "Target Disease" by relative ratio. However, the "Unknown" category is excluded.

1.6 By Nature of Research: No. of Projects and R&D Funding | 1) Second Term Total



Fig. 1.6.1 No. of projects by Nature of Research



Fig. 1.6.2 R&D funding by Nature of Research

Table 1.6.1 No. of projects and R&D funding by Nature of Research

Nature of Research	Abbreviation	No. of projects	R&D funding (Billion JPY)
Pharmaceutical / Medical Device Development	Pharmaceuticals / Med. Devices	5,152	407.4
Basic Biomedical / Etiologic Studies	Biomedical / Etiologic	3,494	177.7
Fact-finding Survey Analysis	Survey Analysis	226	7.8
Medical Technique / Standard Therapy Dev.	Technique / Therapy	1,076	27.7
Research / Drug Discovery Infrastructure Development	Infrastructure	1,516	152.8
Regulatory / Nursing System Improvement and Technical Support	System Improvement	214	4.4
Development, Establishment, and Validation of New Diagnostic / Testing Methods and Systems	Diagnosis / Testing	682	28.5
Evidence Building for Prevention	Prevention	495	16.6
Others	Others	551	41.1
Unknown	Unknown	9	0.2
Total		13,415	864.3

• Source: AMED data (as of November 2025).

1.6 By Nature of Research: No. of Projects and R&D Funding | 2) 5-years Trends



Fig. 1.6.3 Trends in no. of projects by Nature of Research



Fig. 1.6.4 Trends in R&D funding by Nature of Research

Table 1.6.2 Trends in no. of projects and R&D funding by Nature of Research

Nature of Research	Abbreviation	No. of projects					R&D funding (Billion JPY)				
		FY2020	FY2021	FY2022	FY2023	FY2024	FY2020	FY2021	FY2022	FY2023	FY2024
Pharmaceutical / Medical Device Development	Pharmaceuticals / Med. Devices	1,297	973	855	994	1,033	100.0	88.0	64.3	71.0	84.1
Basic Biomedical / Etiologic Studies	Biomedical / Etiologic	526	700	821	730	717	22.3	40.2	41.5	36.4	37.4
Fact-finding Survey Analysis	Survey Analysis	68	59	63	18	18	2.7	1.5	2.1	0.8	0.7
Medical Technique / Standard Therapy Dev.	Technique / Therapy	273	256	269	144	134	6.2	7.4	8.1	3.5	2.5
Research / Drug Discovery Infrastructure Development	Infrastructure	363	299	294	279	281	34.5	27.7	28.2	31.6	30.9
Regulatory / Nursing System Improvement and Technical Support	System Improvement	27	16	14	79	78	0.5	0.2	0.3	1.5	1.9
Development, Establishment, and Validation of New Diagnostic / Testing Methods and Systems	Diagnosis / Testing	125	146	118	153	140	5.0	4.4	4.6	7.5	7.1
Evidence Building for Prevention	Prevention	51	71	76	143	154	1.9	3.2	2.8	4.0	4.7
Others	Others	81	92	105	137	136	4.8	5.0	8.9	11.6	10.9
Unknown	Unknown	3	5	—	—	1	0.03	0.1	—	—	0.03
Total		2,814	2,617	2,615	2,677	2,692	177.9	177.7	160.9	167.6	180.2

- Source: AMED data (as of November 2025).
- Some figures are omitted in graphs.

1.7 By Disease Area: No. of Projects and R&D Funding



Fig. 1.7.1 No. of projects by Disease Area



Fig. 1.7.2 R&D funding by Disease Area

Table 1.7.1 No. of projects and R&D funding by Disease Area

Disease Area	No. of projects					R&D funding (Billion JPY)				
	FY2020*	FY2021	FY2022	FY2023	FY2024	FY2020*	FY2021	FY2022	FY2023	FY2024
Cancer	617	664	648	721	741	26.0	35.9	37.1	37.4	38.4
Lifestyle related diseases	246	201	235	264	274	8.0	8.7	8.9	11.7	13.3
Mental and neurological disorders	275	219	259	284	296	10.5	13.4	18.7	16.2	16.4
Aging and dementia	179	116	131	139	151	10.8	7.8	7.9	7.0	8.6
Rare and intractable diseases	433	380	435	374	363	22.5	22.6	23.4	21.6	23.3
Child health and development	64	93	97	79	70	1.6	3.5	3.0	2.2	2.3
Infectious diseases	631	451	478	431	420	56.6	57.5	35.9	42.7	43.6
Others	732	526	332	385	376	58.8	35.9	25.9	28.9	34.2

- In FY2021 there were multiple choices for "Disease Area" among 22 projects, and all choices were aggregated.
- "Others" includes basic R&D projects on non-specifiable diseases and R&D projects on research / drug discovery infrastructure development.
- Source: AMED data (as of November 2025).

*Since multiple choices for a single project were possible in FY2020, the reference values are presented in Table 1.7.1. They are not shown on the graphs.

1.8 By R&D Objective: No. of Projects and R&D Funding



Fig. 1.8.1 No. of projects by R&D Objective



Fig. 1.8.2 R&D funding by R&D Objective

Table 1.8.1 No. of projects and R&D funding by R&D Objective

R&D Objective	No. of projects					R&D funding (Billion JPY)				
	FY2020	FY2021	FY2022	FY2023	FY2024	FY2020	FY2021	FY2022	FY2023	FY2024
Prevention / Health	665	1,092	1,141	858	893	52.0	93.4	78.6	68.0	70.9
Diagnosis	893	1,080	1,068	1,081	1,074	54.4	63.6	64.5	71.7	73.3
Treatment	1,845	1,886	1,857	1,847	1,868	101.1	111.7	109.7	105.1	114.9
QOL	515	1,062	1,145	1,114	1,171	23.0	55.2	65.0	64.6	70.0
Others	386	262	257	324	296	30.5	17.6	18.6	25.8	25.4

- For a single project, there were possible in multiple choices for develop objectives.
- "Others" includes both of R&D projects on "Research / Drug Discovery Infrastructure Development" and "Basic Biomedical / Etiologic Studies".
- Source: AMED data (as of November 2025).

2.1 By R&D Phase: No. of Projects and R&D Funding | 1) Second Term Total



Fig. 2.1.1 No. of projects by R&D Phase



Fig. 2.1.2 R&D funding by R&D Phase

Table 2.1.1 No. of projects and R&D funding by R&D Phase

R&D Phase	No. of projects	R&D funding (Billion JPY)
Basic / Applied Studies	2,627	135.2
Nonclinical / Pre-clinical	1,124	113.5
Clinical Study	397	35.5
Clinical Trials	835	111.8
Post Marketing	26	0.8
Observational Study, etc.	22	1.1
NA	116	9.4
Unknown	5	0.2
Total	5,152	407.4

- These data show the "R&D Phase" that are required to be attached to projects for "Pharmaceutical / Medical Device Development".
- Source: AMED data (as of November 2025).
- Some figures are omitted in graphs.

2.1 By R&D Phase: No. of Projects and R&D Funding | 2) 5-years Trends



Fig. 2.1.3 Trends in no. of projects by R&D Phase



Fig. 2.1.4 Trends in R&D funding by R&D Phase

Table 2.1.2 Trends in no. of projects and R&D funding by R&D Phase

R&D Phase	No. of projects					R&D funding (Billion JPY)				
	FY2020	FY2021	FY2022	FY2023	FY2024	FY2020	FY2021	FY2022	FY2023	FY2024
Basic / Applied Studies	776	512	384	468	487	44.7	25.8	21.5	21.3	21.9
Nonclinical / Pre-clinical	208	195	208	251	262	16.4	23.1	16.9	25.7	31.5
Clinical Study	87	95	87	63	65	6.6	17.0	4.7	3.5	3.7
Clinical Trials	191	141	125	189	189	25.8	21.2	19.8	19.3	25.6
Post Marketing	1	1	1	9	14	0.04	0.01	0.1	0.2	0.5
Observational Study, etc.	2	8	3	5	4	0.1	0.3	0.2	0.3	0.2
NA	32	16	47	9	12	6.4	0.5	1.1	0.6	0.8
Unknown	—	5	—	—	—	—	0.2	—	—	—
Total	1,297	973	855	994	1,033	100.0	88.0	64.3	71.0	84.1

- These data show the "R&D Phase" that are required to be attached to projects for "Pharmaceutical / Medical Device Development".
- Source: AMED data (as of November 2025).
- Some figures are omitted in graphs.

2.2 By Product Approval Category: No. of Projects and R&D Funding | 1) Second Term Total



Fig. 2.2.1 No. of projects by Product Approval Category



Fig. 2.2.2 R&D funding by Product Approval Category

Table 2.2.1 No. of projects and R&D funding by Product Approval Category

Product Approval Category	No. of projects	R&D funding (Billion JPY)
Pharmaceuticals	2,892	253.3
Medical Devices	973	57.8
Regenerative Medicine Products	905	76.0
In-vitro Diagnostics	188	8.6
NA under the PMD Act	188	11.4
Unknown	6	0.2
Total	5,152	407.4

- These data show the "Product Approval Categories" that are required to be attached to projects for "Pharmaceutical / Medical Device Development".
- Source: AMED data (as of November 2025).
- Some figures are omitted in graphs.

2.2 By Product Approval Category: No. of Projects and R&D Funding | 2) 5-years Trends



Fig. 2.2.3 Trends in no. of projects by Product Approval Category



Fig. 2.2.4 Trends in R&D funding by Product Approval Category

Table 2.2.2 Trends in no. of projects and R&D funding by Product Approval Category

Product Approval Category	No. of projects					R&D funding (Billion JPY)				
	FY2020	FY2021	FY2022	FY2023	FY2024	FY2020	FY2021	FY2022	FY2023	FY2024
Pharmaceuticals	767	585	458	530	552	53.7	62.9	38.8	46.3	51.7
Medical Devices	208	177	201	196	191	18.1	9.3	9.0	9.8	11.7
Regenerative Medicine Products	220	151	149	185	200	19.1	12.8	13.8	12.9	17.4
In-vitro Diagnostics	24	31	27	52	54	0.8	2.2	2.2	1.2	2.2
NA under the PMD Act	77	24	20	31	36	8.4	0.7	0.6	0.8	1.0
Unknown	1	5	—	—	—	0.01	0.2	—	—	—
Total	1,297	973	855	994	1,033	100.0	88.0	64.3	71.0	84.1

- These data show the "Product Approval Categories" that are required to be attached to projects for "Pharmaceutical / Medical Device Development".
- Source: AMED data (as of November 2025).
- Some figures are omitted in graphs.

3.1 No. of Projects and R&D Funding



Fig. 3.1.1 No. of projects in Second Term



Fig. 3.1.2 R&D funding in Second Term



Fig. 3.1.3 Trends in no. of projects



Fig. 3.1.4 Trends in R&D funding

Table 3.1.1 No. of projects and R&D funding

*COVID-19-related budget projects

	FY2020			FY2021			FY2022			FY2023			FY2024			Second Term Total		
	AMED Total	Special Fund Programs	COVID-19*	AMED Total	Special Fund Programs	COVID-19*	AMED Total	Special Fund Programs	COVID-19*	AMED Total	Special Fund Programs	COVID-19*	AMED Total	Special Fund Programs	COVID-19*	AMED Total	Special Fund Programs	COVID-19*
No. of projects	2,814	5	5	2,617	20	15	2,615	47	14	2,677	74	8	2,692	120	6	13,415	266	48
R&D funding (Billion JPY)	177.9	4.0	4.0	177.7	34.4	32.5	160.9	18.5	9.6	167.6	30.1	3.7	180.2	41.9	2.2	864.3	129.0	52.1

- Source: AMED data (as of November 2025).
- Refer to 6.2 for more detailed information on Special Fund Programs. ▶P38

3.2 By Category of Research Institution: No. of Projects and R&D Funding



Fig. 3.2.1 No. of projects by category of Research Institution in Second Term



Fig. 3.2.2 R&D funding by category of Research Institution in Second Term



Fig. 3.2.3 Trends in no. of projects by category of Research Institution



Fig. 3.2.4 Trends in R&D funding by category of Research Institution

Table 3.2.1 No. of projects and R&D funding by category of Research Institution

Category of Research Institution	No. of projects						R&D funding (Billion JPY)					
	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total
Universities, etc.	1	11	27	40	60	139	0.1	2.8	7.6	18.2	20.2	48.9
Incorporated Admin. Agencies / Nat'l Research Institutes	—	1	5	8	19	33	—	0.3	1.3	2.5	2.6	6.7
Companies, etc.	4	8	14	24	39	89	3.9	31.3	9.6	9.1	18.1	72.0
Incorporated Foundations / Associations, etc.	—	—	1	2	2	5	—	—	0.1	0.4	0.9	1.3
Total	5	20	47	74	120	266	4.0	34.4	18.5	30.1	41.9	129.0

• Refer to 6.1 regarding the category of Research Institution. ▶P35
• Source: AMED data (as of November 2025).
• Refer to 6.2 for more detailed information on Special Fund Programs. ▶P38

3.3 By Nature of Research: No. of Projects and R&D Funding



Fig. 3.3.1 No. of projects by Nature of Research in Second Term



Fig. 3.3.2 R&D funding by Nature of Research in Second Term



Fig. 3.3.3 Trends in no. of projects by Nature of Research



Fig. 3.3.4 Trends in R&D funding by Nature of Research

Table 3.3.1 Trends in no. of projects and R&D funding by Nature of Research

Nature of Research	No. of projects						R&D funding (Billion JPY)					
	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total
Pharmaceutical / Medical Device Development	5	11	25	54	83	178	4.0	32.0	12.9	23.6	33.0	105.5
Basic Biomedical / Etiologic Studies	—	3	7	13	19	42	—	1.3	2.3	5.3	6.2	15.1
Fact-finding Survey Analysis	—	—	1	—	—	1	—	—	0.3	—	—	0.3
Medical Technique / Standard Therapy Dev.	—	2	2	—	—	4	—	0.6	0.4	—	—	1.1
Research / Drug Discovery Infrastructure Development	—	1	5	2	8	16	—	0.03	1.2	0.4	0.8	2.4
Development, Establishment, and Validation of New Diagnostic / Testing Methods and Systems	—	1	—	2	5	8	—	0.1	—	0.7	0.8	1.6
Evidence Building for Prevention	—	2	1	1	1	5	—	0.3	0.2	0.04	0.1	0.7
Others	—	—	6	2	4	12	—	—	1.2	0.1	1.1	2.4
Total	5	20	47	74	120	266	4.0	34.4	18.5	30.1	41.9	129.0

•Refer to "Table 1.6.1" regarding the abbreviations for "Nature of Research". ▶P9
•Refer to 6.2 for more detailed information on Special Fund Programs. ▶P38
•Source: AMED data (as of November 2025). •Some figures are omitted in graphs.

3.4 By Disease Area: No. of Projects and R&D Funding



Fig. 3.4.1 No. of projects by Disease Area



Fig. 3.4.2 R&D funding by Disease Area

Table 3.4.1 No. of projects and R&D funding by Disease Area

Disease Area	No. of projects					R&D funding (Billion JPY)				
	FY2020*	FY2021	FY2022	FY2023	FY2024	FY2020*	FY2021	FY2022	FY2023	FY2024
Cancer	—	2	2	6	12	—	1.1	0.4	0.8	3.5
Lifestyle related diseases	—	3	2	2	6	—	1.6	0.4	0.6	0.8
Mental and neurological disorders	—	2	1	3	6	—	0.9	0.7	0.7	1.7
Aging and dementia	—	3	4	4	8	—	1.2	1.0	0.7	2.4
Rare and intractable diseases	—	2	1	5	14	—	1.1	0	0.7	2.9
Child health and development	—	1	—	1	1	—	0.7	—	0.004	0.1
Infectious diseases	5	15	36	51	62	4.0	32.5	16.1	26.1	28.9
Others	—	—	1	2	11	—	—	0.01	0.4	1.6

- In FY2021 there were multiple choices for "Disease Area" among 2 projects, and all choices were aggregated.
- "Others" includes basic R&D projects on non-specifiable diseases and R&D projects on research / drug discovery infrastructure development.
- Source: AMED data (as of November 2025). - Refer to 6.2 for more detailed information on Special Fund Programs. ▶P38

*Since multiple choices for a single project were possible in FY2020, the values are presented in Table 3.4.1 as a reference.

3.5 By R&D Objective: No. of Projects and R&D Funding



Fig. 3.5.1 No. of projects by R&D Objective



Fig. 3.5.2 R&D funding by R&D Objective

Table 3.5.1 No. of projects and R&D funding by R&D Objective

R&D Objective	No. of projects					R&D funding (Billion JPY)				
	FY2020	FY2021	FY2022	FY2023	FY2024	FY2020	FY2021	FY2022	FY2023	FY2024
Prevention / Health	5	20	44	60	80	4.0	34.4	18.5	28.2	33.4
Diagnosis	—	5	16	25	42	—	1.9	5.6	13.1	13.3
Treatment	—	8	19	33	61	—	6.2	6.5	11.3	18.3
QOL	—	6	14	30	53	—	2.1	4.8	10.0	15.3
Others	—	—	2	2	7	—	—	0.1	0.2	0.9

- "Others" include Research / Drug Discovery Infrastructure Development, as well as Basic Biomedical / Etiologic Studies, among others.
- Refer to 6.2 for more detailed information on Special Fund Programs. ▶P38
- In regard to "R&D Objective", multiple objectives are possible for individual projects.
- Source: AMED data (as of November 2025).

3.6 By R&D Phase: No. of Projects and R&D Funding



Fig. 3.6.1 No. of projects by R&D Phase of research for "Pharmaceutical / Medical Device Development" in Second Term



Fig. 3.6.2 R&D funding by R&D Phase of research for "Pharmaceutical / Medical Device Development" in Second Term



Fig. 3.6.3 Trends in no. of projects by R&D Phase of research for "Pharmaceutical / Medical Device Development"



Fig. 3.6.4 Trends in R&D funding by R&D Phase of research for "Pharmaceutical / Medical Device Development"

Table 3.6.1 Trends in no. of projects and R&D funding by R&D Phase of research for "Pharmaceutical / Medical Device Development"

R&D Phase	No. of projects						R&D funding (Billion JPY)					
	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total
Basic / Applied Studies	—	1	3	8	15	27	—	0.3	1.8	2.7	2.1	6.9
Nonclinical / Pre-clinical	—	3	15	28	41	87	—	8.4	2.9	12.2	16.2	39.7
Clinical Study	—	2	2	1	2	7	—	11.5	0.04	0.4	0.6	12.5
Clinical Trials	5	5	5	16	24	55	4.0	11.9	8.1	7.9	13.7	45.6
NA	—	—	—	1	1	2	—	—	—	0.3	0.3	0.7
Total	5	11	25	54	83	178	4.0	32.0	12.9	23.6	33.0	105.5

- These data show the "R&D Phase" that are required to be attached to projects for "Pharmaceutical / Medical Device Development".
- Refer to 6.2 for more detailed information on Special Fund Programs. ▶P38
- Source: AMED data (as of November 2025). • Some figures are omitted in graphs.

3.7 By Product Approval Category: No. of Projects and R&D Funding



Fig. 3.7.1 No. of projects by Product Approval Category of research for "Pharmaceutical / Medical Device Development" in Second Term



Fig. 3.7.2 R&D funding by Product Approval Category of researchfor "Pharmaceutical / Medical Device Development" in Second Term



Fig. 3.7.3 Trends in no. of projects by Product Approval Category of research for "Pharmaceutical / Medical Device Development"



Fig. 3.7.4 Trends in R&D funding by Product Approval Category of research for "Pharmaceutical / Medical Device Development"

Table 3.7.1 Trends in no. of projects and R&D funding by Product Approval Category of research for "Pharmaceutical / Medical Device Development"

Product Approval Category	No. of projects						R&D funding (Billion JPY)					
	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total
Pharmaceuticals	5	11	24	46	64	150	4.0	32.0	12.9	22.4	28.1	99.4
Medical Devices	—	—	—	1	4	5	—	—	—	0.4	0.4	0.8
Regenerative Medicine Products	—	—	1	7	14	22	—	—	0	0.8	4.3	5.1
In-vitro Diagnostics	—	—	—	—	1	1	—	—	—	—	0.1	0.1
Total	5	11	25	54	83	178	4.0	32.0	12.9	23.6	33.0	105.5

- These data show the "Product Approval Categories" that are required to be attached to projects for "Pharmaceutical / Medical Device Development".
- Refer to 6.2 for more detailed information on Special Fund Programs. ▶P38
- Source: AMED data (as of November 2025).

4.1 No. of Projects and R&D Funding



Fig. 4.1.1 No. of projects in Second Term



Fig. 4.1.2 R&D funding in Second Term



Fig. 4.1.3 Trends in no. of projects



Fig. 4.1.4 Trends in R&D funding

Table 4.1.1 Trends in no. of projects and R&D funding

*COVID-19-related budget projects

	FY2020		FY2021		FY2022		FY2023		FY2024		Second Term Total	
	AMED Total	COVID-19*	AMED Total	COVID-19*	AMED Total	COVID-19*	AMED Total	COVID-19*	AMED Total	COVID-19*	AMED Total	COVID-19*
No. of projects	2,814	307	2,617	127	2,615	79	2,677	57	2,692	37	13,415	607
R&D funding (Billion JPY)	177.9	57.1	177.7	45.6	160.9	14.3	167.6	8.2	180.2	5.3	864.3	130.5
R&D funding per project (Billion JPY)	0.06	0.19	0.07	0.36	0.06	0.18	0.06	0.14	0.07	0.14	0.06	0.22

- The R&D funding per project is the average figure.
- Source: AMED data (as of November 2025).

4.2 By Category of Research Institution: No. of Projects and R&D Funding



Fig. 4.2.1 No. of projects by category of Research Institution in Second Term



Fig. 4.2.2 R&D funding by category of Research Institution in Second Term



Fig. 4.2.3 Trends in no. of projects by category of Research Institution



Fig. 4.2.4 Trends in R&D funding by category of Research Institution

Table 4.2.1 Trends in no. of projects and R&D funding by category of Research Institution

Category of Research Institution	No. of projects						R&D funding (Billion JPY)					
	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total
Universities, etc.	209	89	55	41	26	420	29.5	9.0	4.3	3.4	2.4	48.5
Incorporated Admin. Agencies / Nat'l Research Institutes	50	20	14	9	5	98	8.7	2.2	1.1	1.6	0.6	14.2
Companies, etc.	46	17	10	7	6	86	18.3	34.5	8.9	3.2	2.2	67.2
Local Public Entities, etc.	—	1	—	—	—	1	—	0.01	—	—	—	0.01
Incorporated Foundations / Associations, etc.	2	—	—	—	—	2	0.6	—	—	—	—	0.6
Total	307	127	79	57	37	607	57.1	45.6	14.3	8.2	5.3	130.5

• Refer to 6.1 regarding the category of Research Institution. ▶P35
• Source: AMED data (as of November 2025).

4.3 By Nature of Research: No. of Projects and R&D Funding



Fig. 4.3.1 No. of projects by Nature of Research in Second Term



Fig. 4.3.2 R&D funding by Nature of Research in Second Term



Fig. 4.3.3 Trends in no. of projects by Nature of Research



Fig. 4.3.4 Trends in R&D funding by Nature of Research

Table 4.3.1 Trends in no. of projects and R&D funding by Nature of Research

Nature of Research	No. of projects						R&D funding (Billion JPY)					
	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total
Pharmaceutical / Medical Device Development	177	45	18	11	9	260	35.8	38.2	9.5	3.8	2.3	89.7
Basic Biomedical / Etiologic Studies	31	27	22	16	6	102	3.7	1.2	1.3	1.1	0.5	7.9
Fact-finding Survey Analysis	5	3	3	—	—	11	0.2	0.3	0.4	—	—	0.9
Medical Technique / Standard Therapy Dev.	8	6	5	1	1	21	0.6	0.2	0.1	0.1	0.1	1.3
Research / Drug Discovery Infrastructure Development	38	32	24	14	12	120	12.0	4.3	2.0	1.2	1.0	20.5
Development, Establishment, and Validation of New Diagnostic / Testing Methods and Systems	15	7	3	2	1	28	1.8	0.4	0.3	0.4	0.1	3.1
Evidence Building for Prevention	1	6	—	1	—	8	0.1	0.9	—	0.01	—	1.0
Others	32	1	4	12	8	57	2.9	0.02	0.7	1.5	1.2	6.2
Total	307	127	79	57	37	607	57.1	45.6	14.3	8.2	5.3	130.5

• Refer to "Table 1.6.1" regarding the abbreviations for "Nature of Research". ▶P9
• Source: AMED data (as of November 2025).

4.4 By R&D Objective: No. of Projects and R&D Funding



Fig. 4.4.1 No. of projects by R&D Objective



Fig. 4.4.2 R&D funding by R&D Objective

Table 4.4.1 No. of projects and R&D funding by R&D Objective

R&D Objective	No. of projects					R&D funding (Billion JPY)				
	FY2020	FY2021	FY2022	FY2023	FY2024	FY2020	FY2021	FY2022	FY2023	FY2024
Prevention / Health	105	68	47	29	17	22.9	38.7	11.7	5.6	3.3
Diagnosis	105	42	26	26	14	14.9	3.6	2.0	2.7	1.8
Treatment	146	86	44	30	17	19.1	13.8	2.2	2.1	1.3
QOL	24	35	20	15	10	2.6	5.2	1.3	1.5	1.0
Others	41	13	12	9	8	11.6	2.2	1.6	1.1	0.9

- In regard to "R&D Objective", multiple objectives are possible for individual projects.
- Source: AMED data (as of November 2025).

4.5 By R&D Phase: No. of Projects and R&D Funding



Fig. 4.5.1 No. of projects by R&D Phase of research for "Pharmaceutical / Medical Device Development" in Second Term



Fig. 4.5.2 R&D funding by R&D Phase of research for "Pharmaceutical / Medical Device Development" in Second Term



Fig. 4.5.3 Trends in no. of projects by R&D Phase of research for "Pharmaceutical / Medical Device Development"



Fig. 4.5.4 Trends in R&D funding by R&D Phase of research for "Pharmaceutical / Medical Device Development"

Table 4.5.1 No. of projects and R&D funding by R&D Phase of research for "Pharmaceutical / Medical Device Development"

R&D Phase	No. of projects						R&D funding (Billion JPY)					
	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total
Basic / Applied Studies	108	14	8	4	2	136	11.1	1.6	0.6	0.1	0.1	13.5
Nonclinical / Pre-clinical	27	17	3	2	2	51	4.1	12.1	0.8	0.8	0.03	17.9
Clinical Study	15	5	2	—	—	22	3.3	12.0	0.04	—	—	15.4
Clinical Trials	23	8	5	5	5	46	14.6	12.4	8.1	2.9	2.2	40.2
Post Marketing	1	—	—	—	—	1	0.04	—	—	—	—	0.04
Observational Study, etc.	—	1	—	—	—	1	—	0.01	—	—	—	0.01
NA	3	—	—	—	—	3	2.7	—	—	—	—	2.7
Total	177	45	18	11	9	260	35.8	38.2	9.5	3.8	2.3	89.7

•These data show the "R&D Phase" that are required to be attached to projects for "Pharmaceutical / Medical Device Development".
•Source: AMED data (as of November 2025).

4.6 By Product Approval Category: No. of Projects and R&D Funding



Fig. 4.6.1 No. of projects by Product Approval Category of research for "Pharmaceutical / Medical Device Development" in Second Term



Fig. 4.6.2 R&D funding by Product Approval Category of research for "Pharmaceutical / Medical Device Development" in Second Term



Fig. 4.6.3 Trends in no. of projects by Product Approval Category of research for "Pharmaceutical / Medical Device Development"



Fig. 4.6.4 Trends in R&D funding by Product Approval Category of research for "Pharmaceutical / Medical Device Development"

Table 4.6.1 Trends in no. of projects and R&D funding by Product Approval Category of research for "Pharmaceutical / Medical Device Development"

Product Approval Category	No. of projects						R&D funding (Billion JPY)					
	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total
Pharmaceuticals	105	41	18	9	8	181	22.6	37.7	9.5	3.8	2.3	75.9
Medical Devices	44	3	—	—	—	47	9.5	0.5	—	—	—	10.0
Regenerative Medicine Products	1	—	—	1	1	3	0.02	—	—	0.04	0.03	0.1
In-vitro Diagnostics	5	1	—	1	—	7	0.1	0.01	—	0.01	—	0.2
NA under the PMD Act	22	—	—	—	—	22	3.6	—	—	—	—	3.6
Total	177	45	18	11	9	260	35.8	38.2	9.5	3.8	2.3	89.7

•These data show the "Product Approval Categories" that are required to be attached to projects for "Pharmaceutical / Medical Device Development".
•Source: AMED data (as of November 2025).

5.1 Applications, Awards and Success Rates



Fig. 5.1.1 No. of applications, awards and success rates in Second Term



Fig. 5.1.2 Trends in no. of applications, awards and success rates

Table 5.1.1 Trends in no. of applications, awards and success rates

	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total
Applications	4,810	4,021	4,584	4,125	4,180	21,720
Awards	1,098	885	1,075	952	901	4,911
Success rates	22.8%	22.0%	23.5%	23.1%	21.6%	22.6%

- Success rates are the percentage of all awards to the number of applications.
- Source: Published data on AMED open calls (as of November 2025).

5.2 Principal Investigators (PIs) of New Awards: By Gender and Average Age



Fig. 5.2.1 No. of PIs by gender in Second Term



Fig. 5.2.2 Trends in no. of PIs by gender



Fig. 5.2.3 Trends in average age of all PIs and by gender

Table 5.2.1 Trends in no. of PIs by gender and percentage of female PIs

	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total
Male	927	792	839	864	760	4,182
Female	92	96	98	79	113	478
Total	1,019	888	937	943	873	4,660
Percentage of female PIs	9.0%	10.8%	10.5%	8.4%	12.9%	10.3%

Table 5.2.2 Trends in average age of PIs

	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total
Male	50.7	49.5	50.2	49.9	50.3	50.1
Female	46.8	47.6	46.4	48.5	46.6	47.1
Total	50.4	49.3	49.8	49.8	49.8	49.8

- The new awards for a certain fiscal year are the projects launched in that fiscal year.
- The number of PIs is the cumulative number for the new awards in each fiscal year, and their ages are as of the start of each fiscal year of research launch based on their birth dates.
- Source: The Cross-ministerial R&D Management System (e-Rad) (all as of November 2025). Note that data of researchers whose gender and birth date are unknown are not included.

5.3 Principal Investigators (PIs) of New Awards: By Age Group | 1) Total



Fig. 5.3.1 No. of PIs by age group in Second Term



Fig. 5.3.2 Trends in no. of PIs by age group



Fig. 5.3.3 Trends by fiscal year in average age of PIs by age group

Table 5.3.1 Trends in no. of PIs by age group

Age group	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total
<30	3	3	3	1	3	13
30-34	23	27	19	25	24	118
35-39	129	130	116	107	81	563
40-44	153	149	172	179	139	792
45-49	162	145	173	177	183	840
50-54	172	151	146	156	173	798
55-59	205	149	159	134	134	781
60-64	128	100	100	114	104	546
65-69	32	25	38	33	26	154
70≦	12	9	11	17	6	55
Total	1,019	888	937	943	873	4,660

- The new awards for a certain fiscal year are the projects launched in that fiscal year.
- They were calculated by age group based on the number of PIs is the cumulative number for the new awards in each fiscal year, and their ages are as of the start of each fiscal year of research launch based on their birth dates.
- Source: The Cross-ministerial R&D Management System (e-Rad) (all status, as of November 2025). Note that data for which gender and birth date are unknown have been omitted.

5.3 Principal Investigators (PIs) of New Awards: By Age Group | 2) Male PIs



Fig. 5.3.4 No. of male PIs by age group in Second Term



Fig. 5.3.5 Trends in no. of male PIs by age group



Fig. 5.3.6 Trends by fiscal year in average age of male PIs by age group

Table 5.3.2 Trends in no. of male PIs by age group

Age group	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total
<30	3	1	3	1	1	9
30-34	20	24	15	23	19	101
35-39	113	114	100	95	67	489
40-44	131	133	149	165	113	691
45-49	144	120	148	158	158	728
50-54	156	138	132	145	153	724
55-59	196	138	148	121	122	725
60-64	124	94	97	108	96	519
65-69	28	21	36	32	25	142
70≦	12	9	11	16	6	54
Total	927	792	839	864	760	4,182

- The new awards for a certain fiscal year are the projects launched in that fiscal year.
- They were calculated by age group based on the number of PIs is the cumulative number for the new awards in each fiscal year, and their ages are as of the start of each fiscal year of research launch based on their birth dates.
- Source: The Cross-ministerial R&D Management System (e-Rad) (all status, as of November 2025). Note that data for which gender and birth date are unknown have been omitted.

5.3 Principal Investigators (PIs) of New Awards: By Age Group | 3) Female PIs



Fig. 5.3.7 No. of female PIs by age group in Second Term



Fig. 5.3.8 Trends in no. of female PIs by age group



Fig. 5.3.9 Trends by fiscal year in average age of female PIs by age group

Table 5.3.3 Trends in no. of female PIs by age group

Age group	FY2020	FY2021	FY2022	FY2023	FY2024	Second Term Total
<30	—	2	—	—	2	4
30-34	3	3	4	2	5	17
35-39	16	16	16	12	14	74
40-44	22	16	23	14	26	101
45-49	18	25	25	19	25	112
50-54	16	13	14	11	20	74
55-59	9	11	11	13	12	56
60-64	4	6	3	6	8	27
65-69	4	4	2	1	1	12
70≦	—	—	—	1	—	1
Total	92	96	98	79	113	478

- The new awards for a certain fiscal year are the projects launched in that fiscal year.
- They were calculated by age group based on the number of PIs is the cumulative number for the new awards in each fiscal year, and their ages are as of the start of each fiscal year of research launch based on their birth dates.
- Source: The Cross-ministerial R&D Management System (e-Rad) (all status, as of November 2025). Note that data for which gender and birth date are unknown have been omitted.

6.1 Category of Research Institution

Category in the DataBook	Type of entity
Universities, etc.	National Universities Public Universities Private Universities Inter-University Research Institute Corporations, etc.
Incorporated Admin. Agencies / Nat'l Research Institutes	Incorporated Administrative Agencies National Research Institutes
Companies, etc.	Companies Medical Corporations, Social Welfare Corporations, etc.
Local Public Entities, etc.	Local Public Entities Local Incorporated Administrative Agencies
Incorporated Foundations / Associations, etc.	Incorporated Foundations Incorporated Associations Public Interest Corporations Special Corporations and Specially-Authorized Corporations
Others	Religious Corporations Overseas Institutions Others

6.2 Glossary

Term	Description
Awarded project	A general term for R&D projects and their equivalents that are funded by AMED including projects conducted at subsidiary institutions or other subcontracted institutions under projects selected by AMED. Although projects may span multiple years from the start to the end of the research period, in this DataBook, projects starting their first year on or after April 1 of the fiscal year in question, excluding any project existing in previous fiscal years are considered new projects, and others as ongoing projects. The number of projects and R&D funding are aggregated each fiscal year.
COVID-19-related budget projects	Refers to the COVID-19-related R&D projects that AMED supported with supplementary budgets for COVID-19 countermeasures. The COVID-19-related budget projects in the DataBook are based on "AMED R&D Regarding COVID-19 Countermeasures" **https://www.amed.go.jp/content/000112086.pdf** (Japanese language only.)
Cyclic Innovation for Clinical Empowerment (CiCLE)	Through the provision of large-scale and long-term loans (in principle up to 10 years with a ceiling of 10 billion JPY) to bear the burden of technology risks by AMED, AMED is promoting the creation of an infrastructure for innovation to accelerate the R&D and practical application of pharmaceuticals, medical devices and other medical products.

Term	Description
Disease Area	The seven disease areas stipulated in the second Healthcare Policy as being social issues in contemporary and future Japanese society with a view to demographic movement in the year 2040. In the DataBook, in the event that an awarded project does not fit into any of the seven categories or if it is not research regarding a specific disease area, it is treated as "Others". · Cancer · Lifestyle related diseases (including circulatory system and diabetes) · Mental and neurological disorders · Aging and dementia · Rare and intractable diseases · Child health and development · Infectious diseases (including AMR)
ICD-10 Disease Classification	ICD is an abbreviation of "International Statistical Classification of Diseases and Related Health Problems" created and endorsed by the World Health Organization (WHO), and ICD-10 is its 10th revised version. The Ministry of Health, Labour and Welfare of Japan currently compiles the "detailed list of statistical classification of diseases, injuries and causes of death (FY2013 version)", derived from ICD-10 (2023 version), to register the statistical data and medical records in Japan. AMED uses the ICD-10 large categories (chapters) as "Target Disease" categorial tags for the AMED R&D projects. In the DataBook, the ICD-10 category (chapter) of "Neoplasms" is shown as "Cancer (Neoplasms)". Note that in ICD-10 codes for special purposes are used for the provisional assignment of new diseases of uncertain etiology or emergency use, and these include COVID-19. In the DataBook, they are shown as "COVID-19".

6.2 Glossary

Term	Description
Integrated Projects (Second Term)	The six Integrated Projects centering on modalities, based on the second Healthcare Policy. 1) Project for Advanced Drug Discovery and Development 2) Project for Medical Device and Healthcare 3) Project for Regenerative Medicine and Cell and Gene Therapies 4) Project for Genome and Health-Related Data 5) Project for Basic Medical Research 6) Project for Seeds Development and Research Base
Medium- to long-term plan	AMED, as a Japanese National Research and Development Agency, is set to launch a medium- to long-term plan to achieve its objectives, and this is stated in Article 35-5 of the Act on General Rules for Incorporated Administrative Agencies (Act No. 103 of 1999). The period of AMED's first medium- to long-term plan was from FY2015 to FY2019, and the period of the second medium- to long-term plan was from FY2020 to FY2024. First and Second medium- to long-term plan: **https://www.amed.go.jp/koukai/kouhyou.html#anc-3** (Japanese language only.)
Nature of Research	A categorial tag to classify the "Nature of Research" of individual awarded projects, uniquely defined by AMED. Eight categories are listed as below. · Pharmaceutical / Medical Device Development (including development of systems linking to medical device development) · Basic Biomedical / Etiologic Studies · Fact-finding Survey Analysis (including fieldwork, surveillances, and monitoring) · Medical Technique / Standard Therapy Development (including evidence building to improve the quality of medical care by compilation of guidelines and other methods) · Research / Drug Discovery Infrastructure Development (including drug discovery technologies, ICT infrastructure and platforms) · Regulatory / Nursing System Improvement and Technical Support (including advancement of technology supports for the international health system) · Development, Establishment, and Validation of New Diagnostic / Testing Methods and Systems (excluding development of diagnostic drugs and equipment) · Evidence Building for Prevention (including epidemiology studies)
Principal Investigator (PI)	Principal Investigator (PI) of R&D projects awarded by AMED

6.2 Glossary

Term	Description
Product Approval Category	One of the categorial tags for AMED R&D projects. It is attached to one of the four items eligible for AMED R&D support (Pharmaceuticals, Medical devices, Regenerative medicine products, and In-vitro diagnostics) from among the items defined in Article 2 of the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Pharmaceuticals and Medical Devices Act: PMD Act). The attachment of categorial tags is necessary when the "Nature of Research" is "Pharmaceutical / Medical Device Development", but the attachment of categorial tags is optional for projects of different "Nature of Research".
R&D Objective	One of the categorial tags for AMED R&D projects. The "R&D Objective" for the main research themes is categorized into the following four. · Prevention / Health · Diagnosis · Treatment · QOL If R&D projects do not fit into any of the above four or do not have any specific "R&D Objective", they are treated as "Others".
R&D Phase	One of the categorial tags for AMED R&D projects. The "R&D Phase" of R&D support is categorized into Basic Study, Applied Study, Nonclinical Study / Pre-clinical Study, Clinical Study, Clinical Trials, Post Marketing, and Observational Study, etc. The attachment of categorial tags is necessary when the "Nature of Research" is "Pharmaceutical / Medical Device Development", but the attachment of categorial tags is optional for projects of different "Nature of Research".
Second Healthcare Policy	Pursuant to Article 17 of the Health and Medical Strategy Advancement Act (Act No. 48 of 2014), the Healthcare Policy was stipulated by the government to promote in a comprehensive and systematic manner the measures the government should take related to medical R&D and the creation of new industries to contribute to a society in which people enjoy long and healthy lives, in order for the establishment of a society in which the public can live healthy lives and enjoy greater longevity (a society in which people enjoy long and healthy lives). The Second Policy sets the five years from FY2020 to FY2024 as the period covered, and was approved by the Cabinet on March 27, 2020 (and partially revised on April 9, 2021).
Special Fund Programs	Programs that are established pursuant to the Act on Improving the Capacity, and the Efficient Promotion of Research and Development through Promotion of Research and Development System Reform. The programs secure in advance the financial resources for several years, thus enabling flexible support for their stable and efficient implementation.
The Cross-ministerial R&D Management System (e-Rad)	The Cross-ministerial R&D Management System. This is a cross-ministerial system to put online the series of processes regarding R&D management (receipt of application => review => selection => awarded project management=> accomplishment report) centering on the competitive research funding system, which went into operation from January 2009. **https://www.e-rad.go.jp/en/**

Japan Agency for Medical Research and Development

Department of Research and Development Strategy
Division of Research and Development Planning
kaihatukikaku@amed.go.jp

Published in February, 2026